Neurodegeneration Biomarkers in Adult Spinal Muscular Atrophy (SMA) Patients Treated with Nusinersen

Pol Andrés-Benito,Juan Francisco Vázquez-Costa,Nancy Carolina Ñungo Garzón,María J. Colomina,Carla Marco,Laura González,Cristina Terrafeta,Raúl Domínguez,Isidro Ferrer,Mónica Povedano

DOI: https://doi.org/10.3390/ijms25073810

IF: 5.6

2024-03-30

International Journal of Molecular Sciences

Abstract:The objective of this study is to evaluate biomarkers for neurodegenerative disorders in adult SMA patients and their potential for monitoring the response to nusinersen. Biomarkers for neurodegenerative disorders were assessed in plasma and CSF samples obtained from a total of 30 healthy older adult controls and 31 patients with adult SMA type 2 and 3. The samples were collected before and during nusinersen treatment at various time points, approximately at 2, 6, 10, and 22 months. Using ELISA technology, the levels of total tau, pNF-H, NF-L, sAPPβ, Aβ40, Aβ42, and YKL-40 were evaluated in CSF samples. Additionally, plasma samples were used to measure NF-L and total tau levels using SIMOA technology. SMA patients showed improvements in clinical outcomes after nusinersen treatment, which were statistically significant only in walkers, in RULM (p = 0.04) and HFMSE (p = 0.05) at 24 months. A reduction in sAPPβ levels was found after nusinersen treatment, but these levels did not correlate with clinical outcomes. Other neurodegeneration biomarkers (NF-L, pNF-H, total tau, YKL-40, Aβ40, and Aβ42) were not found consistently changed with nusinersen treatment. The slow progression rate and mild treatment response of adult SMA types 2 and 3 may not lead to detectable changes in common markers of axonal degradation, inflammation, or neurodegeneration, since it does not involve large pools of damaged neurons as observed in pediatric forms. However, changes in biomarkers associated with the APP processing pathway might be linked to treatment administration. Further studies are warranted to better understand these findings.

biochemistry & molecular biology,chemistry, multidisciplinary

What problem does this paper attempt to address?

The paper attempts to address the issue of evaluating changes in neurodegenerative disease biomarkers in adult patients with Spinal Muscular Atrophy (SMA) after receiving Nusinersen treatment and their potential value in monitoring treatment response.

Specifically, the researchers focus on the following points:
1. **Evaluating biomarker changes**: By detecting the level changes of biomarkers such as total tau protein, phosphorylated neurofilament heavy chain (pNF-H), neurofilament light chain (NF-L), amyloid precursor protein β fragment (sAPPβ), β-amyloid protein 40 (Aβ40), β-amyloid protein 42 (Aβ42), and YKL-40 in plasma and cerebrospinal fluid samples, to assess the neurodegenerative impact of Nusinersen treatment on adult SMA patients.
2. **Monitoring treatment response**: Exploring whether these biomarkers can serve as effective tools for monitoring clinical improvement in adult SMA patients after receiving Nusinersen treatment.
3. **Understanding treatment mechanisms**: By analyzing the changes in these biomarkers, further understanding the mechanism of Nusinersen treatment in adult SMA patients, especially the changes in biomarkers related to the APP processing pathway.

The background of the study is that although Nusinersen has shown significant efficacy in pediatric SMA patients, its efficacy and biomarker changes in adult SMA patients remain unclear. Therefore, this study aims to fill this knowledge gap and provide scientific evidence for the treatment and monitoring of adult SMA patients.